Carregant...
The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis
INTRODUCTION: Lumacaftor-ivacaftor is indicated for treatment of cystic fibrosis (CF) in patients homozygous for the Phe-508del cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations. In clinical trials, treated patients showed improved pulmonary function, reduced pulmonary exacer...
Guardat en:
| Publicat a: | Expert Opin Drug Saf |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6209511/ https://ncbi.nlm.nih.gov/pubmed/28846049 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14740338.2017.1372419 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|